|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 141.65 USD | -2.51% |
|
+0.41% | +8.00% |
| 01-15 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 01-13 | Illumina CEO Sees Big Growth Opportunity in China | MT |
| Capitalization | 21.64B 18.66B 17.37B 16.17B 30.11B 1,964B 32.39B 200B 78.79B 937B 81.17B 79.5B 3,421B | P/E ratio 2025 * |
31.2x | P/E ratio 2026 * | 31.9x |
|---|---|---|---|---|---|
| Enterprise value | 22.83B 19.68B 18.32B 17.06B 31.76B 2,071B 34.17B 211B 83.09B 988B 85.61B 83.84B 3,608B | EV / Sales 2025 * |
5.32x | EV / Sales 2026 * | 5.04x |
| Free-Float |
79.72% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Illumina, Inc.
| 1 day | -2.51% | ||
| 1 week | +0.41% | ||
| Current month | +8.00% | ||
| 1 month | +7.67% | ||
| 3 months | +47.69% | ||
| 6 months | +46.09% | ||
| Current year | +8.00% |
| 1 week | 140.19 | 151 | |
| 1 month | 129.99 | 151.34 | |
| Current year | 130.42 | 151.34 | |
| 1 year | 68.7 | 151.34 | |
| 3 years | 68.7 | 238.55 | |
| 5 years | 68.7 | 555.77 | |
| 10 years | 68.7 | 555.77 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jacob Thaysen
CEO | Chief Executive Officer | 51 | 24/09/2023 |
Ankur Dhingra
DFI | Director of Finance/CFO | 50 | 14/04/2024 |
Steven Barnard
CTO | Chief Tech/Sci/R&D Officer | - | 08/08/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 71 | 28/11/2012 |
Frances Arnold
BRD | Director/Board Member | 69 | 27/01/2016 |
Philip Schiller
BRD | Director/Board Member | 65 | 27/07/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.51% | +0.41% | +3.12% | -29.57% | 21.64B | ||
| -0.95% | -0.02% | +10.15% | +5.97% | 232B | ||
| -1.17% | -8.74% | -8.40% | +106.64% | 190B | ||
| -1.63% | -1.00% | -2.44% | -13.75% | 167B | ||
| -2.18% | -9.80% | -10.29% | +89.28% | 131B | ||
| -1.07% | -0.45% | -9.22% | -7.81% | 59.92B | ||
| -0.17% | -0.92% | +20.74% | +7.71% | 48.95B | ||
| -3.58% | -5.98% | -3.51% | -11.01% | 39.59B | ||
| -1.20% | +2.02% | +8.62% | +18.10% | 37.52B | ||
| -0.92% | -6.34% | -3.82% | +24.92% | 37.24B | ||
| Average | -1.54% | -3.08% | +0.49% | +19.05% | 96.43B | |
| Weighted average by Cap. | -1.40% | -3.70% | -0.43% | +32.59% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.29B 3.7B 3.44B 3.2B 5.96B 389B 6.42B 39.58B 15.61B 186B 16.08B 15.75B 678B | 4.4B 3.79B 3.53B 3.29B 6.12B 399B 6.58B 40.6B 16.01B 190B 16.49B 16.15B 695B |
| Net income | 658M 567M 528M 492M 915M 59.71B 985M 6.08B 2.4B 28.48B 2.47B 2.42B 104B | 679M 585M 545M 507M 944M 61.58B 1.02B 6.27B 2.47B 29.37B 2.55B 2.49B 107B |
| Net Debt | 1.18B 1.02B 950M 884M 1.65B 107B 1.77B 10.93B 4.31B 51.22B 4.44B 4.35B 187B | 520M 449M 418M 389M 724M 47.21B 779M 4.8B 1.89B 22.52B 1.95B 1.91B 82.23B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 141.65 $ | -2.51% | 1,901,812 |
| 15/01/26 | 145.30 $ | +0.92% | 1,700,422 |
| 14/01/26 | 143.97 $ | -2.05% | 2,065,648 |
| 13/01/26 | 146.99 $ | +0.99% | 2,298,204 |
| 12/01/26 | 145.55 $ | +3.18% | 1,648,889 |
Delayed Quote Nasdaq, January 16, 2026 at 09:00 pm
More quotesTrader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ILMN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
















